Welcome to our website where we’ll try to give some basic information about the Company. As a reporting company, there are significant SEC and Sarbanes-Oxley constraints on what I can say.
Now for some interesting history about discovery and the sheer determinism necessary to fully elucidate initial observations.
In 1928, a physician-bacteriologist named Alexander Fleming, working at St. Mary's Hospital in London returned from a long vacation to find
his bacterial culture plates "contaminated" by what appeared to be a fungus. Thinking his experiments were ruined, he threw the plates into a
liquid antiseptic to first sterilize and then discard them. When a visitor to the lab asked for a tour, he pulled out the only non-submerged
plates to complain about his ruined experiment. Upon closer examination, he found a clear zone around the dead bacterial colonies.
Then he had a "Eureka" moment that led him on a 12 year quest to determine the nature of the toxin from the fungus and the means of isolating it.
I mention this only because Dr. Diwan, the inventor of our technology, spent the same amount of time before he felt that the technology of
building the nanomicelle and attaching the ligand and encapsulated drugs was ready for "prime time." He supported himself by writing software
and receiving grants. Another bit of historical information is the contribution of Nobel Prize winner and the inventor of Quantum Electrodynamics, Richard Feynman. He gave a lecture at Cal Tech in December 1959 entitled "There's plenty of room at the bottom" which essentially defined the
field of nanotechnology. It took many years for the tools to be developed to exploit his theoretical musings. In chemistry, the field of
nanotechnology was advanced by Dr. Richard Smalley, Nobelist at the Rice University. Coincidentally, Dr. Diwan received his PhD in Biochemical Engineering from Rice.
We have had a number of successes in our laboratory and animal studies with our nanoviricides® treatments for various viruses. Notably for influenza, HIV, oral and genital Herpes, Dengue, epidemic kerato-conjunctivitis, and Rabies, among others.
We have now nominated a clinical candidate in our FluCide™ program. We believe this clinical candidate, NV-INF-1, should work against most if not all influenza viruses.
Our other drug programs are also proceeding successfully. We will let you know as they advance further towards human clinical development.
Sincerely,
Eugene Seymour, MD, MPH
Chief Executive Officer.
September 09th, 2011.
